Dr. Freddy Yip is an associate in the firm’s Business Law Department and Life Sciences group. Dr. Yip received his Ph.D. in Molecular Biology in Australia. Prior to joining the legal profession, Dr. Yip worked in various research and development positions in the biopharmaceutical industry for eight years, focusing on preclinical development of novel protein-based drugs. Capitalizing on this background, Dr. Yip has been practicing in the areas of corporate and life sciences laws. He has advised a few local and overseas life sciences and technology companies in licensing, joint venture, strategic and collaboration, equity financing and IPO transactions, as well as a few VC and private equity firms in equity investment transactions. Prior to joining Goodwin, Dr. Yip received his solicitor training in the Hong Kong office of a U.S. law firm. Dr. Yip speaks English, Cantonese, and Mandarin.

叶明晖律师是高赢国际律师事务所商法事务部的一名律师,也是生命科学业务部的成员。叶律师在澳大利亚获得分子生物学博士学位。在加入法律界之前,叶律师在生物制药业研发方面有8年的工作经验,专注于新型蛋白质药物的临床前开发。基于这一背景,叶律师一直从事公司法和生命科学领域的法律工作。叶律师曾为数家本地和外地的生命科学和技术公司提供许可、合资、战略合作、股权融资及IPO交易方面的咨询服务,并为数家风投及私募股权公司提供股权投资交易方面的咨询服务。在加入高赢之前,叶律师在一家美国律师事务所的香港办公室接受律师培训。

叶律师通晓英语、广东话和普通话。

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Dr. Yip’s experience includes representation of:

  • CardioFocus, Inc., in its licensing and distribution agreement with China Grand Pharmaceutical (SEHK: 0512) for the HeartLight X3 System in China, Hong Kong and Macau.
  • Zai Lab Limited (Nasdaq: ZLAB; SEHK: 9688) in its broad strategic collaboration and license agreement with MacroGenics (Nasdaq: MGNX) to develop and commercialize preclinical bispecific antibodies in oncology, involving up to four immuno-oncology molecules.
  • Impact Therapeutics in forming a joint venture with Junshi Biosciences in China to develop and commercialize a PARP inhibitor for the treatment of cancers in Greater China. 
  • Regenacy Pharmaceuticals, Inc. in its formation of Beijing 3E-Regenacy Pharmaceuticals Co., Ltd., a joint venture with 3E Bioventures Capital, for the development of Regenacy’s lead compound ricolinostat, a HDAC6 inhibitor, in mainland China, Hong Kong and Macau.
  • Allogene Therapeutics, Inc. (Nasdaq: ALLO) in its formation of Allogene Overland Biopharm, a joint venture with Overland Pharmaceuticals, for the development, manufacturing and commercialization of AlloCAR T therapies for patients in greater China, Taiwan, South Korea and Singapore.
  • Apollomics, Inc. in its $124 million Series C financing.
  • I-Mab (Nasdaq: IMAB) in its broad, global collaboration with AbbVie (NYSE: ABBV) for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody, for the treatment of multiple cancers.
  • MyoKardia in its strategic collaboration with LianBio to develop and commercialize mavacamten in China and other Asian territories.
  • TransThera Biosciences in its licensing transaction with LG Chem Life Sciences to grant exclusive rights related to TT-01025, a highly selective oral small molecule inhibitor of SSAO/VAP-1.
  • RTW and Ji Xing Pharmaceuticals in their strategic licensing and financing collaboration with Cytokinetics, Incorporated (Nasdaq: CYTK) related to CK-274, a next-generation cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathies (HCMs) and other clinical indications.
  • EpicentRx in its licensing transaction with SciClone to grant an exclusive license related to a small molecule immunotherapy targeting CD47-SIRPα, RRx-001, for the treatment of small-cell lung cancer in the Greater China.
  • Alphamab (SEHK: 9966) in its strategic partnership with Sanofi relating to clinical development of an anti-HER2 bispecific antibody.
  • Cloudbreak Therapeutics in its licensing transaction with China Grand Pharmaceutical and Healthcare holdings Limited (SEHK: 0512) to grant an exclusive license related to a potent multi-kinase inhibitor drug for the treatment of pterygium (CBT-001) in the Greater China.
  • AccuGen Group, an early-stage biotechnology company, in its equity financing by Pharmaron.
  • I-Mab (Nasdaq: IMAB) in its strategic partnership with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk, and Genexine, Inc, relating to commercialization rights of an anti-CD73 antibody (TJD5).
  • Laekna Therapeutics, a PRC-based biotech company, in obtaining from Novartis an exclusive global license on an anti-PD-L1 antibody (FAZ053).
  • Shenzhen Salubris in its licensing and collaboration transaction with Japan Tobacco to obtain an exclusive license related to hypoxia inducible factor inhibitor in the Greater China.
  • VMS Investment Group in Series C investment in New Horizon Health, a PRC- headquartered DNA diagnostic company.*
  • WI Harper Group in Series A2 investment in RWDC Industries Pte Ltd, a Singapore-headquartered biotech start-up.*
  • A group of founding doctors in the formation of Virtus Medical, a dedicated specialty medical services group in Hong Kong, together with HSB Healthcare, Samena Capital and Cenova Ventures.*
  • Vitargent International Holdings Limited, a Hong Kong-based biotesting company, in forming a strategic alliance and an investment agreement with PwC Hong Kong.*
  • Xtep International Holdings Limited (SEHK: 01368), a leading Chinese sports brand, in forming a joint venture with Wolverine World Wide, Inc. (NYSE: WWW).*
  • A Hong Kong-based biomedical company in a number of its equity financing and licensing and collaboration transactions.*
  • A Hong Kong-based DNA diagnostic start-up in its Series A financing.*
  • A Hong Kong-based AI fintech start-up in its Series A financing.*
  • A clinical research institute in a number of its clinical trial agreements with the world’s leading medical institutes and pharmaceutical companies.*
*Denotes experience prior to joining Goodwin

叶律师的主要经验包括代表:

  • CardioFocus与远大医药健康控股有限公司(香港联合交易所代码:0512)就HeartLight X3激光消融平台产品达成在中国大陆、香港地区和澳门地区的许可和分销协议。
  • 再鼎医药(纳斯达克股票代码:ZLAB;香港联合交易所代码:9688)与MacroGenicsda达成广泛战略合作和许可协议,以开发和商业化肿瘤学临床前双特异性抗体,涉及多达四种免疫肿瘤产品。
  • 英派药业与君实生物在中国成立合资公司共同开发PARP抑制剂抗肿瘤药物。
  • Regenacy Pharmaceuticals与3E Bioventures Capital在北京成立合资公司3E-Regenacy Pharmaceuticals,以在中国大陆,香港和澳门开发Regenacy的HDAC6抑制剂ricolinostat。
  • Allogene Therapeutics(纳斯达克股票代码:ALLO)与Overland Pharmaceuticals成立合资公司Allogene Overland Biopharm,专注于为大中华地区,台湾,韩国和新加坡的患者开发、制造和商业化AlloCAR T癌症疗法。
  • Apollomics进行1.24亿美元C轮融资。
  • 代表天境生物(I-Mab Biopharma,纳斯达克股票代码:IMAB)与艾伯維(AbbVie,纽约证券交易所代码:ABBV)开展广泛的全球合作,以开发创新的抗CD47单克隆抗体lemzoparlimab(也称为TJC4)并将其商业化,以治疗多种癌症。
  • MyoKardia(纳斯达克股票代码:MYOK)与联拓生物(LianBio)达成战略合作,以在中国和其他亚洲地区开发和商业化mavacamten。
  • TransThera授予LG Chem其TT01025的开发和商业化的独家权利。TT-01025是SSAO / VAP-1的高度选择性口服小分子抑制剂。
  • RTW和集兴药业与Cytokinetics,Incorporated(纳斯达克股票代码:CYTK)就CK-274进行战略合作、许可协议以及融资合作。CK-274是一种新型口服小分子心肌肌球蛋白抑制剂,可用于治疗肥厚型心肌病(HCMs)。
  • EpicentRx与SciClone就靶向CD47-SIRPα的RRx-001小分子免疫疗法达成大中华区的独家授权许可协议。该疗法用于治疗小细胞肺癌。
  • 康宁杰瑞制药(Alphamab)(香港联合交易所代码:9966)与赛诺菲(Sanofi)就HER2阳性乳腺癌达成战略临床合作。
  • Cloudbreak Therapeutics与远大医药健康控股有限公司(香港联合交易所代码:0512)就用于治疗翼状胬肉有效的多激酶抑制剂药物(CBT-001) 在大中华区的独家许可达成协议。
  • AccuGen Group( 一家处于初始阶段的生物科技公司)通过康龙化成进行股权融资。
  • 天境生物(纳斯达克股票代码: IMAB)与Kalbe Genexine Biologics (Kalbe Farma Tbk, 和 Genexine, Inc的合资公司)就抗CD73抗体(TJD5)的商业化权利达成战略合作伙伴关系。
  • 来凯医药 (一家中国生物科技公司)与诺华 (Novartis)就获得抗PD-L1抗体(FAZ053)的全球独家许可达成协议。
  • 深圳信立泰药业股份有限公司与日本烟草产业株式会社 (JT)就低氧诱导因子抑制剂在大中华区的独家许可达成协议。
  • 鼎珮投资集团作为投资者参与诺辉健康(一家总部设在中国提供的DNA检测服务的公司)的C轮融资。*
  • 中经合集团作为投资者参与RWDC Industries Pte Ltd(总部位于新加坡的初创公司)的A2轮融资。*
  • 组建尚至医疗的创始医生,该集团是香港的一家专业医疗服务集团,与北医疗有限公司、新盟资本和千骥资本共同组建。*
  • 水中银(国际)生物科技有限公司 (一家总部位于香港的生物测试公司)与普华永道香港达成建立战略联盟和投资协议。*
  • 中国内地多品牌体育用品公司特步国际控股有限公司(香港联合交易所代码:01368)与Wolverine World Wide, Inc.(纽约证券交易所代码:WWW)成立合资公司。*
  • 一家总部位于香港的生物医药公司,处理多项股权融资、许可和合作交易*
  • 一家总部位于香港的DNA诊断初创公司的A轮融资。*
  • 一家总部位于香港的人工智能金融科技初创公司的A轮融资。*
  • 一家临床研究所与多家世界领先的医疗机构和制药公司签订了多项临床试验协议。*

*包括加入高赢之前所参与项目。

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

P.C.LL., 2017
The University of Hong Kong
LL.B. (Hons), 2015
Metropolitan Manchester University
Ph.D. in Molecular Biology, 2009
The University of New South Wales
BSc (Hons) in Molecular Biology and Chemistry, 2006
The University of New South Wales

教育背景

法律深造证书, 2017
芝加哥大学
法学士(LL.B.), 2015
曼彻斯特城市大学
分子生物学博士, 2009
新南威尔士大学
分子生物学和化学学士(荣誉), 2006
新南威尔士大学

Admissions

Bar

Hong Kong

执业资格

司法区

香港

Languages

Sprachen

LANGUES

语言

English
Mandarin
Cantonese
英语
普通话
广东话
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师